ELEDON PHARMACEUTICALS, INC. (ELDN)
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
NobelClad Expands Capabilities in the Americas with Weld Overlay Services
Palladyne AI Appoints Former Golden Dome Operational Commander and U.S. Army Space and Missile Defense Commander Lt. Gen. Sean A. Gainey to Defense Advisory Board
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
CI Global Asset Management Announces June 2026 Distributions for Certain CI ETFs
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Lithium Argentina Reports 2026 Annual General Meeting Results
Auddia Announces LT350 Advancement Toward First AI Datacenter Deployment, Engaging Fresh Consulting to Lead Engineering and Development
GXO to Support Action’s Expansion Across Central and Southern Italy with New Distribution Center in Ferentino